December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
First Clinical Results of the Bag-in-the-lens Implantation Preventing PCO
Author Affiliations & Notes
  • VA De Groot
    Department of Ophthalmology University Hospital Antwerp Edegem Belgium
  • M-JJ Tassignon
    Department of Ophthalmology University Hospital Antwerp Edegem Belgium
  • GF J M Vrensen
    Leiden University Medical Center Leiden Netherlands
  • Y Van Tenten
    Department of Ophthalmology University Hospital Antwerp Edegem Belgium
  • Footnotes
    Commercial Relationships   V.A. De Groot, None; M.J. Tassignon, Tassignon P; G.F.J.M. Vrensen, None; Y. Van Tenten, None. Grant Identification: none
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 2985. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      VA De Groot, M-JJ Tassignon, GF J M Vrensen, Y Van Tenten; First Clinical Results of the Bag-in-the-lens Implantation Preventing PCO . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2985.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To report on first clinical results of a new type of intraocular lens and implantation concept, called the "bag-in-the-lens" technique, in order to prevent posterior capsular opacification. Methods: Having performed a matched circular capsulorhexis in both the anterior and posterior capsule, the capsules are inserted in the flange of the intraocular lens, hence the term bag-in-the-lens technique in contrast with the currently used lens-in-the-bag technique. This new implant was implanted in an in vitro human capsular bag model and in 12 eyes of 10 patients with cataract. Lens epithelial cell (LEC) outgrowth and formation of secondary cataract were observed. Results: The in vitro capsular bag model showed LEC proliferation only within the space of the remaining lens bag, provided that both capsular blades were well stretched around the optical part of the rhexis implant. The LEC proliferation was very limited and there was no tendency of proliferation towards the visual axis. In all 12 eyes the optical axis remained clear during follow-up periods between 2 and 24 months. Even in a 4 year old child the visual axis was still perfectly clear after 2 years. Conclusion:This new IOL prevents LEC proliferation in vitro and seems very promising in vivo. Target patients are those at risk for secondary cataract formation, including congenital cataract, uveitis, diabetes or cataract combined with vitrectomy. A two year, multi-centre international trial is currently underway in 8 countries (Canada, Japan, Sweden, Spain, Germany, Israël, United Kingdom, Belgium).

Keywords: 522 posterior capsular opacification (PCO) • 353 clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×